Pharmacological SOS1 inhibitor BI-3406 demonstrates in vivo anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumors
BALTANAS, F. C.; Kramer-Drauberg, M.; Garcia-Navas, R.; Patrucco, E.; Petrini, E.; Arnhof, H.; Olarte-San Juan, A.; Rodriguez-Ramos, P.; Borrajo, J.; Calzada, N.; Castellano, E.; Mair, B.; Kostyrko, K.; Hofmann, M. H.; Ambrogio, C.; Santos, E.
Show abstract
Resistance to KRASmut inhibitors frequently arises, warranting further searches for anti-RAS cancer therapies. We evaluated the tolerability and efficacy of SOS1 pharmacological inhibition in comparison to genetic ablation in different KRAS-dependent tumor settings. Contrary to the rapid lethality caused by SOS1 genetic ablation in SOS2KO mice, SOS1 pharmacological inhibition by its specific inhibitor BI-3406 did not significantly affect animal weight/viability nor cause noteworthy systemic toxicity. In BI-3406-treated KRASmut MEFs, we observed significantly reduced RAS-GTP levels and RAS downstream signaling, as well as decreased tumor burden and slower disease progression resulting from tumor-intrinsic and extrinsic therapeutic drug effects. In vivo analyses of KRASG12D allografts in immunocompromised mice and KRASG12D-driven lung adenocarcinomas in immunocompetent mice showed that systemic BI-3406 treatment impaired tumor growth and downmodulated components of the tumor microenvironment comparably to the KRASG12D inhibitor MRTX1133. Markedly stronger synergistic antitumor effects were observed upon concomitant BI-3406+MRTX113 treatment, confirming SOS1 as an actionable therapy target in RAS-dependent cancers.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer. 95%
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 94%
- Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer 94%
Similar papers in this journal
- GLUT1 inhibition blocks growth of RB1-positive Triple Negative Breast Cancer 95%
- Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot 95%
- Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 95%
Similar papers in this journal
- Histone deacetylase inhibitor induces acetyl-CoA depletion leading to lethal metabolic stress in RAS-pathway activated cells 94%
- Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia 94%
- Paradoxical role of AT-rich interactive domain 1A in restraining pancreatic carcinogenesis 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.